US Bancorp DE Trims Bristol Myers Squibb Stake

Institutional investor reduces holdings in pharmaceutical company by 6.9% in Q3

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

US Bancorp DE, an institutional investor, trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.9% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 1,458,051 shares of the biopharmaceutical company's stock, valued at approximately $65.8 million.

Why it matters

This filing provides insight into the investment strategy and portfolio adjustments of a major institutional investor like US Bancorp DE. Tracking changes in ownership stakes of large investors can offer clues about market sentiment and future performance of individual stocks.

The details

According to the 13F filing, US Bancorp DE sold 107,836 shares of Bristol Myers Squibb during the third quarter. The firm now owns approximately 0.07% of the biopharmaceutical company's outstanding shares. Other notable institutional investors in Bristol Myers Squibb include Charles Schwab Investment Management Inc., Arrowstreet Capital Limited Partnership, and Franklin Resources Inc.

  • US Bancorp DE filed the 13F report for the third quarter of 2026.

The players

US Bancorp DE

A major institutional investor and financial services company headquartered in Minneapolis, Minnesota.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the ongoing portfolio adjustments of large institutional investors like US Bancorp DE as they seek to optimize their holdings in the pharmaceutical sector. The reduced stake in Bristol Myers Squibb may signal a shift in market sentiment or investment strategy for the firm.